Medtronic Expands Affera System CE Mark for Ventricular Arrhythmias
Event summary
- Medtronic received expanded CE Mark indication for its Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias, including VT and PVCs.
- Sphere-9 is the first all-in-one mapping and ablation catheter with dual-energy capabilities (PF and RF) cleared for ventricular ablation in Europe.
- FDA granted Breakthrough Device Designation to Sphere-9 for VT treatment, accelerating U.S. regulatory pathway.
- Sphere VT pivotal trial enrollment underway to support future U.S. approval.
The big picture
This expansion positions Medtronic to address a significant unmet need in ventricular arrhythmia treatment, an area with limited recent innovation. The CE Mark clearance and FDA designation highlight both regulatory recognition of the technology's potential and the strategic importance of dual-energy ablation systems in complex arrhythmia cases.
What we're watching
- Regulatory Momentum
- Whether FDA's Breakthrough Device Designation will accelerate U.S. approval timeline for Sphere-9 in ventricular arrhythmia treatment.
- Market Expansion
- The pace at which Medtronic can capture share in the fast-growing ventricular arrhythmia market with this expanded indication.
- Clinical Validation
- Outcomes from the Sphere VT pivotal trial and their potential impact on physician adoption rates.